Ten-year survival outcome of breast cancer patients in India

Abstract

INTRODUCTION: Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent. MATERIALS AND METHODS: This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India. RESULTS: A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21–86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008–2010). CONCLUSION: Difference between OS and BCSS was found to have an increasing trend during 10–15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008–2010) were favorable predictors for 10-year survival.

To study the survival analysis and recurrence pattern in women treated for breast cancer: Retrospective study, a tertiary cancer center experience from Sub‐Himalayan Region of India

“…According to the American Cancer Society, breast cancer survival rates in the United States are relatively high, with a 91% survival rate at 5 years postdiagnosis and 84% at 10 years. 13 In contrast, a study by Viral et al 14 in India reported a 5-year OS of 79% and a 10-year breast cancerspecific survival of 70%. Another Indian study by Doval et al, 15 which included only early operable breast cancer patients, found a 5-year OS of 94.1% and a disease-free survival (DFS) of 88.1%.…”

“…Four hundred and sixteen patients (62.93%) had angiolymphatic invasion and 119 patients (18.00%) had perineural invasion. Median Ki67% was 40%, median number of nodes dissected were 14, [10][11][12][13][14][15][16][17][18][19] and median number of positive nodes were 4. 2-7,20…”

Targeting autophagy with tamoxifen in breast cancer: From molecular mechanisms to targeted therapy

“…BC seems to be the cause of 18.2% of all cancer deaths, 16.2% of all female cancers, and 22.9% of invasive cancers [4]. Despite extensive research on the underlying processes of BC initiation and progression, patients suffering from BC are still facing high mortality rates [5,6]. BC is generated by a wide range of molecular alterations which makes it a highly polymorphic disease [7].…”

The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience

“…Systemic reviews [ 4 – 7 ] indicate that regular screening mammography can increase the early detection of breast pre-malignancies or malignancies and reduce the risk of late-stage breast cancer, decreasing breast cancer-specific morbidity and mortality. Thus, the ten-year breast cancer-specific survival rate is reported more than 70% in recent studies [ 8 , 9 ].…”